Researcher: Çöpür, Sidar
Loading...
Name Variants
Çöpür, Sidar
Email Address
Birth Date
51 results
Search Results
Now showing 1 - 10 of 51
Publication Metadata only Pathological features of COVID-19 infection from biopsy and autopsy series(Turkish Association of Tuberculosis and Thorax, 2020) Kanbay, Asiye; Afşar, Barış; Elsürer Afşar, Rengin; N/A; N/A; Çöpür, Sidar; Kanbay, Mehmet; Researcher; Faculty Member; School of Medicine; School of Medicine; 368625; 110580Novel coronavirus disease 2019 (COVID-19) which is caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) was first identified in December 2019 in Chinese town Wuhan and considered as a pandemic by World Health Organization. The disease has variety of symptoms including fever, shortness of breath, cough, fatigue, loss of smell and taste and diarrhea. While the majority of cases have mild symptoms, some progress to viral pneumonia, multi-organ failure, or cytokine storm and mortality is mostly caused by hypoxemic respiratory failure. Until now, more than 3.5 million people worldwide were infected and more than 240.000 mortality has been occurred. Thus, there is now evidence the disease may affect variety of organs according to accumulating biopsy and autopsy studies. Such pathological studies have potential role on the understanding of clinical outcomes and in the development of novel targeted therapeutic approaches. Given these aforementioned data, in the current manuscript we have summarized the pathological features of COVID-19 derived from biopsy and autopsy series.Publication Metadata only Uric acid in metabolic syndrome: does uric acid have a definitive role?(Elsevier, 2022) N/A; N/A; N/A; Çöpür, Sidar; Demiray, Atalay; Kanbay, Mehmet; Resercher; Master Student; Faculty Member; School of Medicine; Graduate School of Health Sciences; School of Medicine; 368625; N/A; 110580increased serum uric acid (SUa) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases. although some ambiguity for the exact role of uric acid (Ua) in these diseases is still present, several pathophysiological mechanisms have been identified such as increased oxidative stress, inflammation, and apoptosis. accumulating evidence in genomics enlightens genetic variabilities and some epigenetic changes that can contribute to hyperuricemia. Here we discuss the role of Ua within metabolism and the consequences of asymptomatic hyperuricemia while providing newfound evidence for the associations between Ua and gut microbiota and vitamin D. increased SUa levels and beneficial effects of lowering SUa levels need to be elucidated more to understand its complicated function within different metabolic pathways and set optimal target levels for SUa for reducing risks for metabolic and cardiovascular diseases.Publication Metadata only Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution(Oxford University Press (OUP), 2023) Ortiz, Alberto; Soler, Maria Jose; N/A; Kanbay, Mehmet; Çöpür, Sidar; Mızrak, Berk; Faculty Member; Researcher; Undergraduate Student; School of Medicine; School of Medicine; School of Medicine; 110580; 368625; N/AAcute kidney injury (AKI) is common in hospitalized patients while common risk factors for the development of AKI include postoperative settings, patients with baseline chronic kidney disease (CKD) or congestive heart failure. Intravenous (IV) fluid therapy is a crucial component of care for prevention and treatment of AKI. In this narrative review, we update the approach to IV fluid therapy in hospitalized patients including the timing of fluid prescription, and the choice of fluid type, amount and infusion rate along with the potential adverse effects of various crystalloid and colloid solutions, addressing specifically their use in patients with acute kidney disease, CKD or heart failure, and their potential impact on the risk of hospital-acquired AKI.Publication Metadata only Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease(Springer, 2021) Afsar, Baris; Sag, Alan A.; Siriopol, Dimitrie; Kuwabara, Masanari; Badarau, Silvia; Covic, Adrian; Ortiz, Alberto; N/A; Kanbay, Mehmet; Çöpür, Sidar; Bülbül, Mustafa Cem; Faculty Member; Researcher; Researcher; School of Medicine; School of Medicine; School of Medicine; 110580; 368625; 327626The most common cause of liver disease worldwide is now non-alcoholic fatty liver disease (NAFLD). NAFLD refers to a spectrum of disease ranging from steatosis to non-alcoholic steatohepatitis, causing cirrhosis, and ultimately hepatocellular carcinoma. However, the impact of NAFLD is not limited to the liver. NAFLD has extra-hepatic consequences, most notably, cardiovascular and renal disease. NAFLD and chronic kidney disease share pathogenic mechanisms including insulin resistance, lipotoxicity, inflammation and oxidative stress. Not surprisingly, there has been a recent surge in efforts to manage NAFLD in an integrated way that not only protects the liver but also delays comorbidities such as chronic kidney disease. This concept of simultaneously addressing the main disease target and comorbidities is key to improve outcomes, as recently demonstrated by clinical trials of SGLT2 inhibitors and GLP1 receptor agonists in diabetes. HIF activators, already marketed in China, also have the potential to protect both liver and kidney, as suggested by preclinical data. This review concisely discusses efforts at identifying common pathogenic pathways between NAFLD and chronic kidney disease with an emphasis on potential paradigm shifts in diagnostic workup and therapeutic management.Publication Metadata only Intensive blood pressure control on dementia in patients with chronic kidney disease: potential reduction in disease burden(Elsevier, 2022) Berkkan, Metehan; Sarafidis, Pantelis; N/A; N/A; Çöpür, Sidar; Kanbay, Mehmet; Researcher; Faculty Member; School of Medicine; School of Medicine; 368625; 110580Chronic kidney disease (CKD) and dementia are both common comorbidities creating considerable morbidity and mortality, especially in the elderly population with potential interactions. Even though various hypothetical mechanisms underlying the pathophysiology of increased risk of dementia and cognitive impairment in CKD patients have been implicated, no consensus has been reached so far. Recent clinical trials have investigated the therapeutic role of intensive blood pressure control on the risk of dementia in CKD patients with potentially improved outcomes. However, such trials have significant limitations that may influence the outcome and lack specific management guidelines. We reviewed the role of blood pressure and other factors on the risk of dementia in CKD patients which is an issue with high potential for clinical implications that may improve morbidity, mortality, and health expenditures along with its' potential pathophysiological mechanisms and future guidance.Publication Metadata only COVID-19 pandemic and mental health concerns: what should we expect?(Klinik Psikiyatri Dergisi, 2020) Çöpür, Mazlum; Çöpür, Sidar; Researcher; School of Medicine; 368625COVID-19 Pandemic and mental health concerns: What should we expect? / Öz: COVID-19 Pandemisi ve psikiyatrik endişeler: Bundan sonraki süreçte ne beklemeliyiz?Publication Metadata only Abdominal compartment syndrome: an often overlooked cause of acute kidney injury(Springer Heidelberg, 2022) Basile, Carlo; N/A; N/A; N/A; N/A; Çöpür, Sidar; Berkkan, Metehan; Hasbal, Nuri Barış; Kanbay, Mehmet; Resercher; Undergraduate Student; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 368625; N/A; 143778; 110580Abdominal compartment syndrome (ACS) is defined as any organ dysfunction caused by intra-abdominal hypertension (IAH), referred as intra-abdominal pressure (IAP) >= 12 mm Hg according to the World Society of Abdominal Compartment Syndrome. Abdominal compartment syndrome develops in most cases when IAP rises above 20 mmHg Abdominal compartment syndrome, while being a treatable and even preventable condition if detected early in the stage of intra-abdominal hypertension, is associated with high rates of morbidity and mortality if diagnosis is delayed: therefore, early detection is essential. Acute kidney injury (AKI) is a common comorbidity, affecting approximately one in every five hospitalized patients, with a higher incidence in surgical patients. AKI in response to intra-abdominal hypertension develops as a result of a decline in cardiac output and compression of the renal vasculature and renal parenchyma. In spite of the high incidence of intra-abdominal hypertension, especially in surgical patients, its potential role in the pathophysiology of AKI has been investigated in very few clinical studies and is commonly overlooked in clinical practice despite being potentially treatable and reversible. Aim of the present review is to illustrate the current evidence on the pathophysiology, diagnosis and therapy of intra-abdominal hypertension and abdominal compartment syndrome in the context of AKI. [GRAPHICS] .Publication Metadata only New perspectives in attention deficit hyperactivity disorder: possible link to oxytocin(Dr. Mladen Stojanovic University Hospital, 2021) Çöpür, Mazlum; Çöpür, Sidar; Researcher; School of Medicine; 368625N/APublication Metadata only Metabolically healthy obesity: misleading phrase or healthy phenotype?(Elsevier B.V., 2023) Gaipov, Abduzhappar; Kuwabara, Masanari; Hornum, Mads; Van Raalte, Daniel H.; Tanrıöver, Cem; Çöpür, Sidar; Özlüşen, Batu; Akcan, Rüştü Emre; Kanbay, Mehmet; Undergraduate Student; Researcher; Undergraduate Student; Undergraduate Student; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; 368625; N/A; N/A; 110580Obesity is a heterogenous condition with multiple different phenotypes. Among these a particular subtype exists named as metabolically healthy obesity (MHO). MHO has multiple definitions and its prevalence varies according to study. The potential mechanisms underlying the pathophysiology of MHO include the different types of adipose tissue and their distribution, the role of hormones, inflammation, diet, the intestinal microbiota and genetic factors. In contrast to the negative metabolic profile associated with metabolically unhealthy obesity (MUO), MHO has relatively favorable metabolic characteristics. Nevertheless, MHO is still associated with many important chronic diseases including cardiovascular disease, hypertension, type 2 diabetes, chronic kidney disease as well as certain types of cancer and has the risk of progression into the unhealthy phenotype. Therefore, it should not be considered as a benign condition. The major therapeutic alternatives include dietary modifications, exercise, bariatric surgery and certain medications including glucagon-like peptide-1 (GLP-1) analogs, sodium-glucose cotransporter-2 (SGLT-2) inhibitors and tirzepatide. In this review, we discuss the significance of MHO while comparing this phenotype with MUO.Publication Metadata only Responses to hypoxia: how fructose metabolism and hypoxia-inducible factor-1a pathways converge in health and disease(Springer Nature, 2023) Kanbay, Mehmet; Çöpür, Sidar; Altıntaş, Alara; Yavuz, Furkan; Faculty Member; Researcher; Undergraduate Student; Undergraduate Student; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 110580; 368625; N/A; N/APurpose of Review: Oxygen is critical for the high output of energy (adenosine triphosphate) generated by oxidative phosphorylation in the mitochondria, and when oxygen delivery is impaired due to systemic hypoxia, impaired or reduced delivery of red blood cells, or from local ischemia, survival processes are activated. Recent Findings: One major mechanism is the activation of hypoxia-inducible factors (HIFs) that act to reduce oxygen needs by blocking mitochondrial function and stimulating glucose uptake and glycolysis while also stimulating red blood cell production and local angiogenesis. Recently, endogenous fructose production with uric acid generation has also been shown to occur in hypoxic and ischemic tissues where it also appears to drive the same functions, and indeed, there is evidence that many of hypoxia-inducible factors effects may be mediated by the stimulation of fructose production and metabolism. Unfortunately, while being acutely protective, these same systems in overdrive lead to chronic inflammation and disease and may also be involved in the development of metabolic syndrome and related disease. The benefit of SGLT2 inhibitors may act in part by reducing the delivery of glucose with the stimulation of fructose formation, thereby allowing a conversion from the glycolytic metabolism to one involving mitochondrial metabolism. Summary: The use of hypoxia-inducible factor stabilizers is expected to aid the treatment of anemia but, in the long-term, could potentially lead to worsening cardiovascular and metabolic outcomes. We suggest more studies are needed on the use of these agents.